The TSX Venture Exchange has a strong track record of helping early-stage health and life sciences companies raise patient capital. In 2023, nine new life sciences companies went public on the TSX and TSXV, raising a total of $13 billion in equity capital over the past five years. Eupraxia Pharmaceuticals, Hamilton Thorne, and Quipt Home Medical are examples of companies that have demonstrated significant growth after graduating from TSXV to the TSX. The Canadian life sciences industry is experiencing growth, with key trends like AI integration and high occupancy rates in commercial real estate contributing to the sector’s expansion and innovation.
Source link
Importance of Patient Capital in Life Sciences
